medigraphic.com
Instituto Nacional de Salud Pública

2005, Número 5

Siguiente >>

salud publica mex 2005; 47 (5)


- La práctica del tratamiento supervisado en un programa de control de la tuberculosis del municipio de Ribeirão Preto, São Paulo, Brasil (1998-2001)
- Prevalencia del VPH en sexoservidoras de Durango, México

Cardozo GR

Idioma: Español
Referencias bibliográficas: 57
Paginas: 325-326
Archivo PDF: 85.62 Kb.


FRAGMENTO

Señor editor: la tuberculosis fue declarada por la Organización Mundial de Salud, en 1993, como emergencia mundial, por lo que recomendó la estrategia Directly Observed Therapy Short-Course (DOTS), que en español se le conoce como Tratamiento Acortado Estrictamente Supervisado (TAES), con el propósito de mejorar la situación epidemiológica de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. What is DOTS. A guide to understanding the WHO- recommended

  2. TB Control Strategy Known as DOT. Ginebra: WHO (WHOICDS/CPC/TB/99.270), 1999.

  3. Reigota R M S. A valiação do controle da tuberculose pulmonar no município de Bauru -

  4. SP implantayao do tratamento supervisionado, 1999/2000. Tesis. Botucatu (SP): Esco1a de

  5. Enfermagem de Ribeirão Preto/USP, 2001.

  6. Pinho J L , Nogueira P A. Tratamento supervisionado em tuberculose no município de

  7. Taboão da Serra, Sao Paulo 1998-1999. Bol Pneumol Sanitaria (Rio de Janeiro) 2001; 9(1):

  8. 13-18.

  9. World Health Organization.Global tuberculosis control - surveillance, planning,

  10. financing. WHO Report 2004 [monografía en internet]. Ginebra: WHO, 2004 [consultado

  11. 2004 abril 5]. Disponible en: http://www.who.intltb/publications/globalreport/2004/enlBrazil.pdf

  12. Morse D. Directly observed therapy for tuberculosis. BMJ 1996; 312: 719-720.

  13. OPS. Programas Nacionales de Control de TB. México, D.F.: Oficina Regional de la OMS.

  14. (OPS/HCP/HCT176/00), 2000.

  15. Lee E T. Statistical method for survival data analysis. Nueva York: John Wiley & Sons, 1992.

  16. Ministério da Saúde. Manual Técnico para o Controle da Tb 2002. Brasília (D.F.): Ministério da Saúde; Caderno de Atenção Básica No. 6), 2002.

  17. Frieden T, Driver C. Tuberculosis control: Past 10 years and future progress. J Tuberculosis 2003; 83 (issues 1-3):82-85.

  21. Secretaría de Salud. Dirección General de Epidemiología. Histopathological Registry of

  22. Malignant. México, D.F.: SSA, 1996.

  23. Fu YS, Reagan JW, Richart RM. Definition of precursors. Gynecol Oncol 1981;12:220-231.

  24. WHO. Infecciones genitales por papilomavirus humanos y cáncer: memorándum de una

  25. reunión de la OMS. Bol Oficina Sanit Panam 1987;65:120-137.

  26. Ludicke F, Stalberg A, Vassilakos P, Major AL, Campana A. High-and intermediate-risk human papillomavirus infection in sexually active adolescent females. J Pediatr Adolesc Gynecol 2001;14(4):171-174.

  27. Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, Conde-González CJ, Zampilpa-Mejía LG,

  28. García Cisnseros S et al. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers frm Mexico City. Sex Transm Dis. 2001;28(3):125-130.

  29. Rodríguez-Reyes ER, Cerda-Flores RM, Solís-Rios NP, Quiñones-Pérez JM, Cortés-Gutiérrez EI. Identification and typification of the human papiloma virus in women using the “Timely Detection of Cancer” program in Durango, Mexico. Ginecol Obsted Mex. 2003;71:471-475.

  30. Mak R, Van Renterghen L, Cuvelier C. Cervical smears and human papillomavirus

  31. typing in sex workers. Sex Transm Infect 2004;80:(2)118-120.

  32. Chan R, Khoo L, Ho TH, Koh CF, Lee ILU, Yam KL et al. A comparative study of cervical

  33. cytology, colposcopy and PCR for HPV in female sex workers in Singapore. Int J STD

  34. AIDS. 2001;12(3):159-163.

  35. Tideman RL, Thompson C, Rose B, Gilmour S, Marks C, Van Beak I et al. Cervical human

  36. papillomavirus infections in commercial sex workers-risk factors and behaviours. Int J STD AIDS: 2003;14(2):840-847.

  37. Choi BS, Kim O, Park MS, Kim KS, Jeong JK, Lee JS. Genital human papillomavirus genotyping by HPV oligonucleotide microarry in Korean commercial sex workers. J Med Virol

  38. 2003;71(3):440-445.

  39. World Health Organization. What is DOTS. A guide to understanding the WHO- recommended TB Control Strategy Known as DOT. Ginebra: WHO (WHOICDS/CPC/TB/99.270), 1999.

  40. Reigota RMS. A valiação do controle da tuberculose pulmonar no município de Bauru-SP implantayao do tratamento supervisionado, 1999/2000. Tesis. Botucatu (SP): Esco1a de Enfermagem de Ribeirão Preto/USP, 2001.

  41. Pinho JL, Nogueira P A. Tratamento supervisionado em tuberculose no município de Taboão da Serra, Sao Paulo 1998-1999. Bol Pneumol Sanitaria (Rio de Janeiro) 2001; 9(1): 13-18.

  42. World Health Organization.Global tuberculosis control-surveillance, planning, financing. WHO Report 2004 [monografía en internet]. Ginebra: WHO, 2004 [consultado 2004 abril 5]. Disponible en: http://www.who.intltb/publications/globalreport/2004/enlBrazil.pdf

  43. Morse D. Directly observed therapy for tuberculosis. BMJ 1996; 312: 719-720.

  44. OPS. Programas Nacionales de Control de TB. México, D.F.: Oficina Regional de la OMS. (OPS/HCP/HCT176/00), 2000.

  45. Lee E T. Statistical method for survival data analysis. Nueva York: John Wiley & Sons, 1992.

  46. Ministério da Saúde. Manual Técnico para o Controle da Tb 2002. Brasília (D.F.): Ministério da Saúde; Caderno de Atenção Básica No. 6), 2002.

  47. Frieden T, Driver C. Tuberculosis control: Past 10 years and future progress. J Tuberculosis 2003; 83 (issues 1-3):82-85.

  48. Secretaría de Salud. Dirección General de Epidemiología. Histopathological Registry of Malignant. México, D.F.: SSA, 1996.

  49. Fu YS, Reagan JW, Richart RM. Definition of precursors. Gynecol Oncol 1981;12:220-231.

  50. WHO. Infecciones genitales por papilomavirus humanos y cáncer: memorándum de una reunión de la OMS. Bol Oficina Sanit Panam 1987;65:120-137.

  51. Ludicke F, Stalberg A, Vassilakos P, Major AL, Campana A. High-and intermediate-risk human papillomavirus infection in sexually active adolescent females. J Pediatr Adolesc Gynecol 2001;14(4):171-174.

  52. Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, Conde-González CJ, Zampilpa-Mejía LG, García Cisnseros S et al. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers frm Mexico City. Sex Transm Dis. 2001;28(3):125-130.

  53. Rodríguez-Reyes ER, Cerda-Flores RM, Solís-Rios NP, Quiñones-Pérez JM, Cortés-Gutiérrez EI. Identification and typification of the human papiloma virus in women using the “Timely Detection of Cancer” program in Durango, Mexico. Ginecol Obsted Mex. 2003;71:471-475.

  54. Mak R, Van Renterghen L, Cuvelier C. Cervical smears and human papillomavirus typing in sex workers. Sex Transm Infect 2004;80:(2)118-120.

  55. Chan R, Khoo L, Ho TH, Koh CF, Lee ILU, Yam KL et al. A comparative study of cervical cytology, colposcopy and PCR for HPV in female sex workers in Singapore. Int J STD AIDS. 2001;12(3):159-163.

  56. Tideman RL, Thompson C, Rose B, Gilmour S, Marks C, Van Beak I et al. Cervical human papillomavirus infections in commercial sex workers-risk factors and behaviours. Int J STD AIDS: 2003;14(2):840-847.

  57. Choi BS, Kim O, Park MS, Kim KS, Jeong JK, Lee JS. Genital human papillomavirus genotyping by HPV oligonucleotide microarry in Korean commercial sex workers. J Med Virol 2003;71(3):440-445.




2020     |     www.medigraphic.com